Deep Response in Multiple Myeloma: A Critical Review

BioMed Research International
Mariateresa FulcinitiJoaquin Martinez-Lopez

Abstract

Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients' survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Sep 13, 2003·Blood·Bart BarlogieJohn Crowley
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Apr 6, 2007·British Journal of Haematology·Marie-Christine KyrtsonisGerassimos A Pangalis
Jun 22, 2007·The New England Journal of Medicine·Robert A KyleS Vincent Rajkumar
Feb 16, 2010·Cytometry. Part B, Clinical Cytometry·Bruno PaivaAlberto Orfao
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco LadettoAntonio Palumbo
Sep 2, 2010·Current Opinion in Oncology·David GrimwadeSylvie Freeman
Jan 11, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carlos Fernández de LarreaJoan Bladé
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Mar 25, 2011·Nature·Michael A ChapmanTodd R Golub
Apr 13, 2011·Blood·Joaquin Martinez-LopezUNKNOWN Programa para el Estudio de la Terapé utica en Hemopatía Maligna
Jun 17, 2011·Clinical Chemistry·W Greg MillerCatharine M Sturgeon
Dec 1, 2011·Blood·Bruno PaivaUNKNOWN PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study G
Apr 13, 2012·Nature Reviews. Cancer·Gareth J MorganFaith E Davies
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Oct 4, 2012·Blood·Monika BrüggemannMichael Kneba
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy C RawstronRoger G Owen
Oct 15, 2013·British Journal of Haematology·Joaquin Martinez-LopezUNKNOWN GEM (Grupo Español Multidisciplinar de Melanoma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas)
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz
Jan 17, 2014·Expert Review of Hematology·Annamaria BrioliElena Zamagni
Oct 28, 2014·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Tomas KalinaAlberto Orfao
Jun 20, 2015·Blood·Joaquín Martínez-LópezUNKNOWN Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative

❮ Previous
Next ❯

Citations

Jul 4, 2017·European Journal of Cancer Care·V InnaoC Musolino
Oct 24, 2017·International Journal of Laboratory Hematology·I V GaltsevaL P Mendeleeva
Aug 22, 2020·Evolutionary Applications·Elsa Hansen, Andrew F Read
Jan 30, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauNizar J Bahlis
Sep 10, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhengrui XiaoKourong Miao
Feb 25, 2021·The New England Journal of Medicine·Nikhil C MunshiJesús San-Miguel
Sep 25, 2021·Journal of Hematology & Oncology·Craig T Wallington-Beddoe, Rachel L Mynott

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
biopsies
PCR
imaging techniques
imaging technique

Software Mentioned

LymphoSIGHT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Bruno PaivaGrupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Asher A Chanan-Khan, Sergio Giralt
© 2022 Meta ULC. All rights reserved